Pembrolizumab, Axitinib Combo for Advanced Kidney Cancer Granted Priority Review Designation
February 18th 2019Officials with the FDA have granted Priority Review to Merck’s supplemental Biologics License Application (sBLA) for pembrolizumab (Keytruda) for use in combination with axitinib (Inlyta, Pfizer) as first-line treatment for advanced renal cell carcinoma (RCC).
Read More
Pregnant Women at Higher Risk for Influenza-Associated Hospitalization
February 18th 2019Writing in The Journal of Infectious Disease, they noted that pregnant women tend to be treated as high-priority patients when it comes to influenza prevention and treatment, but they said there is relatively little evidence clarifying exactly how outcomes differ for pregnant women versus nonpregnant women.
Read More
FDA Authorizes First Interoperable Insulin Pump for Customized Diabetes Treatment
February 15th 2019Officials with the FDA have permitted marketing of the Tandem Diabetes Care t:Slim X2 insulin pump with interoperable technology (interoperable t:Slim X2) for delivering insulin under the skin for children and adults with diabetes.
Read More